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The biology of fibrosis is an excellent
example of a biological process of great
clinical relevance in which many different
cells and molecular pathways are interact-
ing with each other. Many of the key cells
and molecules have been identified, yet
there is a lack of understanding of how
the whole system can be manipulated at
different stages from initial fibrogenesis,
established fibrosis and during regression.
When dealing with such complex systems
hypothesis driven research has been the
central driving force of scientific discov-
ery. Such research begins by developing a
hypothesis followed by a process of using
the methods of analysis to prove its valid-
ity. In the context of biological research,
“proving” is most simply explained as
“testing”. The more stringent the test, the
greater the likelihood that the hypothe-
sis is sound, and represents the reality. In
contrast to other powerful ideas, hypoth-
esis driven research cannot be credited
to a single event, or person. There is no
Newton’s Principia, or Darwin’s Origins,
that can be used as inspiration and as a
cornerstone. The idea of hypothesis driven
research coalesced around a number of
trends and people. This general shift into
existence also leaves it open to a drift into
something else, something that should be
recognized as failing the central tenant
of the hypothesis driven process which
is to test the hypothesis under rigorous
conditions.
The reality of such a drift is most eas-
ily identified in the current process of
undertaking biomedical research and then
assembling, writing, and submitting an
article. Although authors are intimately
familiar with the basis of hypothesis
driven research, what is actually done fre-
quently resembles an attempt to high-
light and showcase the hypothesis. An
example is the use of in vivo experi-
mental models to demonstrate the role
of a molecule in a particular disease
process. Subtleties of the model and
the time points for analysis are often
selected to provide positive data, which has
silently become the surrogate goal of sci-
entific projects. After submission of the
manuscript, the interaction with review-
ers often most resembles a scientific and
psychological joust, with the reviewer act-
ing as the surrogate tester for the author’s
hypothesis.
In many ways this is unavoidable, as
the review process is a global quality con-
trol measure. Shifting the responsibility of
testing a hypothesis onto the reviewer is
however deeply flawed. After the struc-
ture of the project is in place, and has
been executed, there is relatively little
room for the reviewer to maneuver. To
engineer a rigorous test of the hypoth-
esis after the work has been conducted
will require in most cases an unaccept-
able level of redesign and new experi-
mental data. The limits of the current
situation can be seen in the expanding
pool of molecules which are shown to be
absolutely vital for an experimental dis-
ease process such as fibrosis. Each report
of the lack of fibrosis in the absence of a
particular molecule is progress; however
from a larger perspective such individual
and disconnected bodies of information
may obfuscate opportunities for more
important insights. Are all these molecules
equally important in the development
of fibrosis; are there particular situations
where some are more important than
others?
Any workable change will have to be
built into the experimental process, and
not be engineered by a reviewer after com-
pletion of the project. This requires us to
address the role of negative data in bio-
logical studies. Negative data is frequently
seen as a failure at an experimental or
conceptual level, and even as a threat to
the overall research project. Should neg-
ative data be deemed a failure that could
financially and intellectually bankrupt a
research group? There are clearly situa-
tions where negative data is expected and
is informative. A simple example is a dose
response curve, where the contribution of
positive and negative data in the genera-
tion of new information is in balance. This
example provides a useful insight into one
way by which to also regain the balance
in the author-reviewer relationship for the
responsibility of testing the hypothesis. For
positive findings there should to be an
expectation that in addition to provid-
ing evidence supporting the hypothesis the
author needs to experimentally demon-
strate the limits of the findings. With the
example of in vivo models of fibrosis, is
there a difference between the experimen-
tal and control groups at all time points
(or just the one time point selected to
show a difference), in many strains of
mice, in multiple organs? All these ques-
tions cannot be answered for every posi-
tive finding in every paper. If however all
papers are expected to provide experimen-
tal data which actively tests the limits of
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their findings, there will be a much greater
likelihood that the findings from individ-
ual studies can be related to each other.
This will rebalance our relationship to neg-
ative data which will be seen as better
defining the position of the positive data
in relation to the rest of the field. Most
importantly it will place the author back
into the role of the scientist which is a good
place to be.
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